Dear Editor,

We thank Prof. Alavian for his interest in our paper. The preferential route for hepatitis B (HB) vaccine administration remains controversial in hemodialysis (HD) patients. Our study aiming to compare intramuscular (IM) or intradermal (ID) inoculations was discontinued six months after starting, due to a Safety Monitoring Committee recommendation, since IM vaccination converted 62.3% of the patients, whereas the ID only 13.3%. These results would not allow ethically crossing the groups as proposed. Besides, the aim was to include only naïve patients. However, of those eight patients who did not respond to ID vaccine, seven were submitted to IM injections: three achieved adequate anti-HB levels and four did not. As emphasized in the text, one of the possible causes to the unresponsiveness was the presence of associated inflammation.\(^1\) The vaccine dose applied (in micrograms!) may also have been one of the reasons.

References